KEGG   DRUG: SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
Entry
D12336                      Drug                                   
Name
SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373;
SARS-CoV-2 rS;
Novavax Covid-19 vaccine (TN);
Nuvaxovid (TN)
Product
  Other
NOVAVAX COVID-19 VACCINE, ADJUVANTED (Novavax)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN04
Product: D12336<JP/US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN04 Covid-19, protein subunit
      D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373 <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    COVID-19 Vaccine (Subunit)
     D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12336
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12336
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12336
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system